Dean L. Schorno
2020 - Rigel Pharmaceuticals
In 2020, Dean L. Schorno earned a total compensation of $1.2M as Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $155,952 |
|---|---|
| Option Awards | $613,158 |
| Salary | $424,360 |
| Other | $9,054 |
| Total | $1,202,524 |
Schorno received $613.2K in option awards, accounting for 51% of the total pay in 2020.
Schorno also received $156K in non-equity incentive plan, $424.4K in salary and $9.1K in other compensation.
Rankings
In 2020, Dean L. Schorno's compensation ranked 7,825th out of 13,090 executives tracked by ExecPay. In other words, Schorno earned more than 40.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,825 out of 13,090 | 40th |
Division Manufacturing | 3,306 out of 5,618 | 41st |
Major group Chemicals And Allied Products | 1,341 out of 2,251 | 40th |
Industry group Drugs | 1,164 out of 1,951 | 40th |
Industry Pharmaceutical Preparations | 868 out of 1,456 | 40th |
Source: SEC filing on April 6, 2021.
Schorno's colleagues
We found four more compensation records of executives who worked with Dean L. Schorno at Rigel Pharmaceuticals in 2020.
2020
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
2020
Dolly Vance
Rigel Pharmaceuticals
Executive Vice President, Corporate Affairs, General
2020
David Santos
Rigel Pharmaceuticals
Executive Vice President and Chief Commercial Officer
2020
Wolfgang Dummer
Rigel Pharmaceuticals